Display Settings:

Format

Send to:

Choose Destination
Transpl Infect Dis. 2010 Oct;12(5):428-31. doi: 10.1111/j.1399-3062.2010.00519.x.

Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.

Author information

  • 1Unit√† Operativa Complessa di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy.

Abstract

Leishmaniasis is a zoonosis caused by a protozoan of the Leishmania genus. First-line treatment for all forms is currently represented by the use of antimony derivatives, although toxic effects and the number of resistant strains in both immunocompromised and immunocompetent patients is increasing. Liposomal amphotericin B (L-AMB) is less toxic, more effective, and better tolerated, especially in human immunodeficiency virus-negative immunocompromised patients. We present 2 cases of transplanted patients affected by visceral leishmaniasis treated successfully with L-AMB.

© 2010 John Wiley & Sons A/S.

PMID:
20534035
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Blackwell Publishing
    Write to the Help Desk